| Strategy | Cost (£) per subject | Effectiveness (Quality adjusted life years, QALY) | Incremental cost effectiveness ratio (ICER) |
|---|---|---|---|
| No surveillance | 1932 | 14.23 | |
| Aspirin and Statin | 1735 | 14.27 | |
| Surveillance 5-yearly | 3653 | 14.6 | 5953 |
| Surveillance 3-yearly | 4418 | 14.65 | 13094 |
| Surveillance 2-yearly | 5184 | 14.69 | 21763 |